253 related articles for article (PubMed ID: 26118502)
1. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
2. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
3. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Shi J; Wang E; Zuber J; Rappaport A; Taylor M; Johns C; Lowe SW; Vakoc CR
Oncogene; 2013 Feb; 32(7):930-8. PubMed ID: 22469984
[TBL] [Abstract][Full Text] [Related]
4. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
5. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
6. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
8. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
9. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a.
Shields BJ; Jackson JT; Metcalf D; Shi W; Huang Q; Garnham AL; Glaser SP; Beck D; Pimanda JE; Bogue CW; Smyth GK; Alexander WS; McCormack MP
Genes Dev; 2016 Jan; 30(1):78-91. PubMed ID: 26728554
[TBL] [Abstract][Full Text] [Related]
11. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.
Tan J; Jones M; Koseki H; Nakayama M; Muntean AG; Maillard I; Hess JL
Cancer Cell; 2011 Nov; 20(5):563-75. PubMed ID: 22094252
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
[TBL] [Abstract][Full Text] [Related]
13. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
Jamalpour M; Bergquist E; Welsh M
Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
[TBL] [Abstract][Full Text] [Related]
14. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
15. PRC2 represses transcribed genes on the imprinted inactive X chromosome in mice.
Maclary E; Hinten M; Harris C; Sethuraman S; Gayen S; Kalantry S
Genome Biol; 2017 May; 18(1):82. PubMed ID: 28468635
[TBL] [Abstract][Full Text] [Related]
16. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.
Bergerson RJ; Collier LS; Sarver AL; Been RA; Lugthart S; Diers MD; Zuber J; Rappaport AR; Nixon MJ; Silverstein KA; Fan D; Lamblin AF; Wolff L; Kersey JH; Delwel R; Lowe SW; O'Sullivan MG; Kogan SC; Adams DJ; Largaespada DA
Blood; 2012 May; 119(19):4512-23. PubMed ID: 22427200
[TBL] [Abstract][Full Text] [Related]
17. miR-150 blocks MLL-AF9-associated leukemia through oncogene repression.
Bousquet M; Zhuang G; Meng C; Ying W; Cheruku PS; Shie AT; Wang S; Ge G; Wong P; Wang G; Safe S; Zhou B
Mol Cancer Res; 2013 Aug; 11(8):912-22. PubMed ID: 23604034
[TBL] [Abstract][Full Text] [Related]
18. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1.
Kawagoe H; Kawagoe R; Sano K
Leukemia; 2001 Nov; 15(11):1743-9. PubMed ID: 11681416
[TBL] [Abstract][Full Text] [Related]
19. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
[TBL] [Abstract][Full Text] [Related]
20. Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.
Kamezaki K; Luchsinger LL; Snoeck HW
Exp Hematol; 2014 Mar; 42(3):192-203.e1. PubMed ID: 24269847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
